Is CONDITION AGGRAVATED a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed CONDITION AGGRAVATED.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported CONDITION AGGRAVATED to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and CONDITION AGGRAVATED. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause CONDITION AGGRAVATED, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes CONDITION AGGRAVATED. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if CONDITION AGGRAVATED ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing CONDITION AGGRAVATED: 1
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where CONDITION AGGRAVATED is a reported side effect: 0.0300%

FDA reports of any drug causing CONDITION AGGRAVATED : 52236
Average percentage for all medicated patients where CONDITION AGGRAVATED is reported as a complication: 0.3274%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with CONDITION AGGRAVATED:

AVONEX (3416 patients)
ENBREL (3225 patients)
ASPIRIN (2977 patients)
LASIX (2034 patients)
METHOTREXATE (1650 patients)
PREDNISONE (1628 patients)
FUROSEMIDE (1516 patients)
PREDNISOLONE (1498 patients)
LIPITOR (1437 patients)
OMEPRAZOLE (1411 patients)
NEURONTIN (1290 patients)
DIGOXIN (1252 patients)
NEXIUM (1230 patients)
HUMIRA (1206 patients)
FOLIC ACID (1183 patients)
REBIF (1183 patients)
LISINOPRIL (1183 patients)
SYNTHROID (1069 patients)
REMICADE (1009 patients)
ACETAMINOPHEN (1008 patients)
PLAVIX (1004 patients)
VIOXX (1001 patients)
XANAX (991 patients)
ALBUTEROL (990 patients)
ATENOLOL (981 patients)
ZOLOFT (974 patients)
TRACLEER (966 patients)
LEVOTHYROXINE SODIUM (961 patients)
COUMADIN (956 patients)
ALLOPURINOL (930 patients)
NORVASC (907 patients)
EFFEXOR XR (906 patients)
SIMVASTATIN (905 patients)
LEXAPRO (894 patients)
CELEBREX (883 patients)
EFFEXOR (882 patients)
SEROQUEL (857 patients)
WARFARIN SODIUM (852 patients)
LORAZEPAM (850 patients)
LYRICA (821 patients)
FORTEO (794 patients)
HYDROCHLOROTHIAZIDE (793 patients)
PRISTIQ (774 patients)
AMBIEN (766 patients)
POTASSIUM CHLORIDE (755 patients)
LANTUS (737 patients)
PROTONIX (729 patients)
CLONAZEPAM (725 patients)
IBUPROFEN (703 patients)
OXYCONTIN (693 patients)
KEPPRA (687 patients)
PREDNISONE TAB (681 patients)
PRILOSEC (666 patients)
DIOVAN (659 patients)
LANSOPRAZOLE (655 patients)
GABAPENTIN (648 patients)
ADVAIR DISKUS 100/50 (643 patients)
BACLOFEN (642 patients)
ZYPREXA (637 patients)
FOSAMAX (633 patients)
PREVACID (632 patients)
METFORMIN HCL (632 patients)
SPIRONOLACTONE (623 patients)
RISPERDAL (610 patients)
SPIRIVA (607 patients)
DIAZEPAM (604 patients)
PAXIL (599 patients)
SINGULAIR (585 patients)
CYMBALTA (582 patients)
ALDACTONE (560 patients)
KLONOPIN (550 patients)
ZOCOR (524 patients)
PROZAC (523 patients)
SOLIRIS (522 patients)
ATIVAN (522 patients)
VICODIN (518 patients)
VITAMIN D (518 patients)
CITALOPRAM HYDROBROMIDE (511 patients)
TEGRETOL (511 patients)
INSULIN (504 patients)
ALPRAZOLAM (502 patients)
ENALAPRIL MALEATE (499 patients)
TOPROL-XL (487 patients)
PREMARIN (480 patients)
AVANDIA (477 patients)
AMLODIPINE (475 patients)
MORPHINE (467 patients)
METOPROLOL TARTRATE (464 patients)
FAMOTIDINE (463 patients)
TRAZODONE HCL (454 patients)
TRAMADOL HCL (448 patients)
CRESTOR (447 patients)
LIORESAL (444 patients)
LAMICTAL (439 patients)
WELLBUTRIN (438 patients)
PEG-INTRON (437 patients)
COREG (435 patients)
CARVEDILOL (433 patients)
ACTOS (429 patients)
LAMOTRIGINE (429 patients)
TOPAMAX (428 patients)
RAMIPRIL (426 patients)
CARBAMAZEPINE (419 patients)
RISPERIDONE (417 patients)
ZYRTEC (408 patients)
CELEXA (408 patients)
METOCLOPRAMIDE (407 patients)
OXYCODONE HCL (396 patients)
BYETTA (394 patients)
VALIUM (391 patients)
CALCIUM (390 patients)
REGLAN (388 patients)
NITROGLYCERIN (388 patients)
LEVAQUIN (387 patients)
MIRTAZAPINE (386 patients)
SOLU-MEDROL (381 patients)
ZANTAC (379 patients)
PERCOCET (376 patients)
FLUOXETINE (374 patients)
LOVENOX (374 patients)
FENTANYL (372 patients)
DEPAKOTE (371 patients)
CYCLOPHOSPHAMIDE (367 patients)
AMIODARONE HCL (365 patients)
DEXAMETHASONE (365 patients)
BENADRYL (362 patients)
HEPARIN SODIUM INJECTION (359 patients)
GLUCOPHAGE (355 patients)
CYCLOSPORINE (344 patients)
RANITIDINE (344 patients)
AMITRIPTYLINE HCL (343 patients)
BEXTRA (339 patients)
AMARYL (337 patients)
CIPROFLOXACIN (337 patients)
RIBAVIRIN (330 patients)
VANCOMYCIN (329 patients)
ACCUTANE (328 patients)
MULTI-VITAMIN (328 patients)
VOLTAREN (328 patients)
CLONIDINE (327 patients)
ACTONEL (325 patients)
RISPERDAL CONSTA (323 patients)
ATROVENT (323 patients)
COZAAR (321 patients)
MULTI-VITAMINS (318 patients)
BETASERON (318 patients)
TRILEPTAL (316 patients)
METOPROLOL (315 patients)
PAROXETINE HCL (313 patients)
AMLODIPINE BESYLATE (312 patients)
PREDONINE (311 patients)
PROVIGIL (311 patients)
VALPROATE SODIUM (310 patients)
AMOXICILLIN (308 patients)
LEVETIRACETAM (306 patients)
ZOMETA (305 patients)
ATORVASTATIN CALCIUM (303 patients)
ACETYLSALICYLIC ACID SRT (303 patients)
METHYLPREDNISOLONE (302 patients)
FERROUS SULFATE TAB (301 patients)
DILANTIN (300 patients)
BACTRIM (297 patients)
GLYBURIDE (295 patients)
PROGRAF (292 patients)
XOLAIR (290 patients)
HEPARIN (289 patients)
MORPHINE SULFATE (288 patients)
XYREM (288 patients)
BISOPROLOL FUMARATE (287 patients)
TYSABRI (285 patients)
SYMBICORT (284 patients)
VELCADE (282 patients)
COMBIVENT (281 patients)
ASCORBIC ACID (280 patients)
CIMZIA (280 patients)
MAGNESIUM OXIDE (278 patients)
ALLEGRA (276 patients)
OXYGEN (276 patients)
SUBOXONE (274 patients)
MIRAPEX (274 patients)
CALCIUM CARBONATE (273 patients)
FLONASE (271 patients)
TYLENOL (269 patients)
NAPROXEN (268 patients)
ACYCLOVIR (266 patients)
ABILIFY (264 patients)
AZATHIOPRINE (263 patients)
FLOMAX (263 patients)
REVLIMID (261 patients)
PANTOPRAZOLE SODIUM (257 patients)
ZOLPIDEM TARTRATE (257 patients)
REBETOL (256 patients)
GLIPIZIDE (256 patients)
METFORMIN (255 patients)
ZITHROMAX (255 patients)
NAMENDA (255 patients)
HUMALOG (254 patients)
LORTAB (253 patients)
REMERON (249 patients)
NIFEDIPINE (248 patients)
PROCRIT (247 patients)
METOPROLOL SUCCINATE (246 patients)
ZOFRAN (243 patients)
HALOPERIDOL (242 patients)
CORDARONE (242 patients)
FLEXERIL (241 patients)
LOPRESSOR (241 patients)
DURAGESIC-100 (241 patients)
LITHIUM CARBONATE (240 patients)
VENTOLIN (239 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about CONDITION AGGRAVATED and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.